Morgan Stanley raised earnings forecasts on Merck and expects the pharmaceutical firm's sales of Januvia, a new diabetes treatment, to come in higher than current expectations. Recent comments by Dr.
A popular diabetes drug has fallen prey to nitrosamine impurities—again. And for once, it isn’t metformin. The potential cancer agent Nitroso-STG-19, also known as NTTP, has surfaced in certain ...
WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for JANUVIA(TM) (sitagliptin), the only DPP-4 inhibitor ...
Januvia (sitagliptin) is a prescription oral tablet that’s taken to help manage blood sugar levels in people with type 2 diabetes. Januvia can cause mild to serious side effects, such as headache. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback